Hyalcis
Hyaluronic-Cisplatin Film for Implant in Malignant Mesothelioma Recurrence
Total Cost €
0EC-Contrib. €
0Partnership
0Views
0Hyalcis project word cloud
Explore the words cloud of the Hyalcis project. It provides you a very rough idea of what is the project "Hyalcis" about.
Project "Hyalcis" data sheet
The following table provides information about the project.
| Coordinator |
PLUMESTARS SRL
Organization address contact info |
| Coordinator Country | Italy [IT] |
| Project website | http://www.plumestars.com |
| Total cost | 71˙429 € |
| EC max contribution | 50˙000 € (70%) |
| Programme |
1. H2020-EU.3. (PRIORITY 'Societal challenges) 2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs) 3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies) |
| Code Call | H2020-SMEInst-2018-2020-1 |
| Funding Scheme | SME-1 |
| Starting year | 2019 |
| Duration (year-month-day) | from 2019-05-01 to 2019-10-31 |
Partnership
Take a look of project's partnership.
| # | ||||
|---|---|---|---|---|
| 1 | PLUMESTARS SRL | IT (PARMA PR) | coordinator | 50˙000.00 |
Map
Project objective
Hyalcis is a novel medicinal product, based on an innovative biodegradable film technology, for the prevention of the recurrence after surgery of malignant pleural mesothelioma. The proposing company, PlumeStars s.r.l., has successfully applied to the European Medical Agency, obtaining in 2016 the orphan designation for Hyalcis. This entitles PlumeStars as unique provider of the product, i.e, a polymeric film to treat pleura mesothelioma, for which there are no satisfactory curative methods. To capture this unique business opportunity, the Phase 1 project will develop a detailed Business Plan achievable within 6 months, including technical feasibility assessment based on qualified feedback and requirements from users, detailed market analysis, competitors analysis, industrialization planning, key partnerships preparation, knowledge protection and financial planning. Mesothelioma is a very aggressive form of cancer linked to asbestos use in construction and industry. It is difficult to diagnose, highly resistant to treatment and full recovery is extremely rare. Over 43,000 people die every year worldwide for the disease and that 10,000 new cases of mesothelioma combined in Europe, North America, Japan and Australia occur each year. The solution developed by PlumeStars is a hydrophilic, thin and flexible film, sufficiently resistant to be applied intrapleural or in other districts, adhering to the mesothelial or epithelial surfaces. The cisplatin release from the film is prolonged providing high local concentrations of anticancer drug, precisely in situ where the residual tumor could develop. This introduces significant benefits in terms of effectiveness, limiting tumor recurrence, low toxicity and increased safety and efficiency. This benefits have been confirmed in the tests already carried out on animals. PlumeStars aims at reaching 25% of the 200M€/year target market in 5 years, including 2 years for industrialization and registration.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HYALCIS" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "HYALCIS" are provided by the European Opendata Portal: CORDIS opendata.
More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)
MindTrack (2019)
Analysis of eye vergence responses for the early detection and monitoring of cognitive and mental disorders
Read More